Literature DB >> 8825358

Differential desensitization of mu- and delta- opioid receptors in selected neural pathways following chronic morphine treatment.

F Noble1, B M Cox.   

Abstract

1. Morphine produces a plethora of pharmacological effects and its chronic administration induces several side-effects. The cellular mechanisms by which opiates induce these side-effects are not fully understood. Several studies suggest that regulation of adenylyl cyclase activity by opioids and other transmitters plays an important role in the control of neural function. 2. The aim of this study was to evaluate desensitization of mu- and delta- opioid receptors, defined as a reduced ability of opioid agonists to inhibit adenylyl cyclase activity, in four different brain structures known to be involved in opiate drug actions: caudate putamen, nucleus accumbens, thalamus and periaqueductal gray (PAG). Opiate regulation of adenylyl cyclase in these regions has been studied in control and morphine-dependent rats. 3. The chronic morphine treatment used in the present study (subcutaneous administration of 15.4 mg morphine/rat/day for 6 days via osmotic pump) induced significant physical dependence as indicated by naloxone-precipitated withdrawal symptoms. 4. Basal adenylyl cyclase in the four brain regions was not modified by this chronic morphine treatment. In the PAG and the thalamus, a desensitization of mu- and delta-opioid receptors was observed, characterized by a reduced ability of Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO; mu), Tyr-D-Pen-Gly-Phe-D-Pen (DPDPE; delta) and [D-Ala2]-deltorphin-II (DT-II; delta) to inhibit adenylyl cyclase, activity following chronic morphine treatment. 5. The opioid receptor desensitization in PAG and thalamus appeared to be heterologous since the metabotropic glutamate receptor agonists, L-AP4 and glutamate, and the 5-hydroxytryptamine (5-HT)1A receptor agonist, R(+)-8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT), also showed reduced inhibition of adenylyl cyclase activity following chronic morphine treatment. 6. In the nucleus accumbens and the caudate putamen, desensitization of delta-opioid receptor-mediated inhibition without modification of mu-opioid receptor-mediated inhibition was observed. An indirect mechanism probably involving dopaminergic systems is proposed to explain the desensitization of delta-mediated responses and the lack of mu-opioid receptor desensitization after chronic morphine treatment in caudate putamen and nucleus accumbens. 7. These results suggest that adaptive responses occurring during chronic morphine administration are not identical in all opiate-sensitive neural populations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8825358      PMCID: PMC1909383          DOI: 10.1111/j.1476-5381.1996.tb15169.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  53 in total

1.  Role of different brain structures in the expression of the physical morphine withdrawal syndrome.

Authors:  R Maldonado; L Stinus; L H Gold; G F Koob
Journal:  J Pharmacol Exp Ther       Date:  1992-05       Impact factor: 4.030

2.  Changes in response rates and reinforcement thresholds for intracranial self-stimulation during morphine withdrawal.

Authors:  G J Schaefer; R P Michael
Journal:  Pharmacol Biochem Behav       Date:  1986-12       Impact factor: 3.533

3.  Neural basis of psychomotor stimulant and opiate reward: evidence suggesting the involvement of a common dopaminergic system.

Authors:  M A Bozarth
Journal:  Behav Brain Res       Date:  1986-11       Impact factor: 3.332

Review 4.  Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?

Authors:  R Bandler; M T Shipley
Journal:  Trends Neurosci       Date:  1994-09       Impact factor: 13.837

5.  Chronic morphine administration causes region-specific increase of brain type VIII adenylyl cyclase mRNA.

Authors:  I Matsuoka; R Maldonado; N Defer; F Noël; J Hanoune; B P Roques
Journal:  Eur J Pharmacol       Date:  1994-07-15       Impact factor: 4.432

Review 6.  Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature.

Authors:  G R Martin; P P Humphrey
Journal:  Neuropharmacology       Date:  1994 Mar-Apr       Impact factor: 5.250

Review 7.  Molecular biology of 5-HT receptors.

Authors:  F G Boess; I L Martin
Journal:  Neuropharmacology       Date:  1994 Mar-Apr       Impact factor: 5.250

8.  Convergence of deep somatic and visceral nociceptive information onto a discrete ventrolateral midbrain periaqueductal gray region.

Authors:  K A Keay; C I Clement; B Owler; A Depaulis; R Bandler
Journal:  Neuroscience       Date:  1994-08       Impact factor: 3.590

9.  Physical dependence produced by central morphine infusions: an anatomical mapping study.

Authors:  M A Bozarth
Journal:  Neurosci Biobehav Rev       Date:  1994       Impact factor: 8.989

10.  Differential regulation of D1 dopamine receptor- and of A2a adenosine receptor-stimulated adenylyl cyclase by mu-, delta 1-, and delta 2-opioid agonists in rat caudate putamen.

Authors:  F Noble; B M Cox
Journal:  J Neurochem       Date:  1995-07       Impact factor: 5.372

View more
  19 in total

Review 1.  G protein-coupled receptor kinase/beta-arrestin systems and drugs of abuse: psychostimulant and opiate studies in knockout mice.

Authors:  Laura M Bohn; Raul R Gainetdinov; Marc G Caron
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 2.  Mu opioid receptor regulation and opiate responsiveness.

Authors:  Kirsten M Raehal; Laura M Bohn
Journal:  AAPS J       Date:  2005-10-19       Impact factor: 4.009

3.  Chronic administration of morphine is associated with a decrease in surface AMPA GluR1 receptor subunit in dopamine D1 receptor expressing neurons in the shell and non-D1 receptor expressing neurons in the core of the rat nucleus accumbens.

Authors:  Michael J Glass; Diane A Lane; Eric E O Colago; June Chan; Stefan D Schlussman; Yan Zhou; Mary Jeanne Kreek; Virginia M Pickel
Journal:  Exp Neurol       Date:  2008-01-26       Impact factor: 5.330

Review 4.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

5.  Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance.

Authors:  L J Sim-Selley; K L Scoggins; M P Cassidy; L A Smith; W L Dewey; F L Smith; D E Selley
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

6.  Agonist treatment did not affect association of mu opioid receptors with lipid rafts and cholesterol reduction had opposite effects on the receptor-mediated signaling in rat brain and CHO cells.

Authors:  Peng Huang; Wei Xu; Su-In Yoon; Chongguang Chen; Parkson Lee-Gau Chong; Ellen M Unterwald; Lee-Yuan Liu-Chen
Journal:  Brain Res       Date:  2007-10-12       Impact factor: 3.252

7.  Brain region-specific N-glycosylation and lipid rafts association of the rat mu opioid receptor.

Authors:  Peng Huang; Chongguang Chen; Wei Xu; Su-In Yoon; Ellen M Unterwald; John E Pintar; Yulin Wang; Parkson Lee-Gau Chong; Lee-Yuan Liu-Chen
Journal:  Biochem Biophys Res Commun       Date:  2007-10-31       Impact factor: 3.575

Review 8.  Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.

Authors:  Nobue Kitanaka; Junichi Kitanaka; F Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R Uhl
Journal:  Synapse       Date:  2008-09       Impact factor: 2.562

9.  Prohormone convertase 2 (PC2) null mice have increased mu opioid receptor levels accompanied by altered morphine-induced antinociception, tolerance and dependence.

Authors:  K Lutfy; D Parikh; D L Lee; Y Liu; M G Ferrini; A Hamid; T C Friedman
Journal:  Neuroscience       Date:  2016-05-18       Impact factor: 3.590

10.  Enhanced opioid efficacy in opioid dependence is caused by an altered signal transduction pathway.

Authors:  S L Ingram; C W Vaughan; E E Bagley; M Connor; M J Christie
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.